T1	intervention 0 41	Cediranib in combination with fulvestrant
T2	eligibility 592 660	Postmenopausal women with hormone-sensitive metastatic breast cancer
T3	outcome-Measure 701 732	progression-free survival (PFS)
T5	intervention-participants 933 935	31
T6	control 940 947	placebo
T7	control-participants 951 953	31
T8	outcome 1096 1099	PFS
T11	iv-cont-median 1137 1140	223
T12	cv-cont-median 1145 1153	112 days
T14	iv-bin-percent 1178 1180	22
T15	cv-bin-percent 1185 1188	8 %
T16	outcome 1257 1260	CBR
T17	iv-bin-percent 1265 1269	42 %
T18	outcome 1300 1320	adverse events (AEs)
T19	outcome 1347 1355	diarrhea
T20	iv-bin-percent 1357 1361	68 %
T21	outcome 1364 1371	fatigue
T22	iv-bin-percent 1373 1377	61 %
T23	outcome 1383 1395	hypertension
T24	iv-bin-percent 1397 1401	55 %
T25	outcome 1408 1434	incidence of grade â‰¥ 3 AEs
T26	iv-bin-percent 1436 1440	68 %
T27	cv-bin-percent 1445 1449	32 %
T28	outcome 1452 1463	serious AEs
T29	iv-bin-percent 1465 1469	48 %
T30	cv-bin-percent 1474 1478	13 %
T31	outcome 1481 1500	discontinuation AEs
T32	iv-bin-percent 1502 1506	39 %
T33	cv-bin-percent 1511 1515	10 %
T34	outcome 1522 1561	cediranib dose reductions/interruptions
T35	iv-bin-percent 1563 1567	74 %
T36	cv-bin-percent 1572 1576	32 %
T4	outcome 1173 1176	ORR
T9	outcome-Measure 763 792	objective response rate (ORR)
T10	outcome-Measure 794 814	duration of response
T13	outcome-Measure 816 843	clinical benefit rate (CBR)
T37	outcome-Measure 845 864	safety/tolerability
T38	outcome-Measure 869 890	pharmacokinetics (PK)
